2022
DOI: 10.47750/pnr.2022.13.s06.442
|View full text |Cite
|
Sign up to set email alerts
|

Quantification of an Anti-Rheumatic Agent: Upadacitinib in Biological Fluid (Plasma) By LC- MS/MS

Abstract: Aim: Upadacitinib is a Janus kinase/signal transducers and activators of transcription (JAKs) of cytoplasmic tyrosine kinase that has been proven to be effective in treating inflammatory conditions and various immunological diseases/disorders, including rheumatoid arthritis. Tofacitinib and ruxolitinib, which are members of this drug's first generation, did not affect JAK1/JAK3 or JAK1/JAK2 receptors specifically due to a lack of subtype selectivity. As far as we are aware, there is currently no method for the… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
references
References 15 publications
0
0
0
Order By: Relevance